InnoCare Pharma (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.
The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.
ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.
Beijing InnoCare Pharma Tech and Keymed Biosciences' (HKG:2162) unit Keymed Biosciences (Chengdu) each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。